Petros Pharmaceuticals Stock Investor Sentiment

PTPI Stock  USD 0.27  0.02  6.90%   
Under 61% of Petros Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Petros Pharmaceuticals suggests that many traders are alarmed. Petros Pharmaceuticals' investing sentiment shows overall attitude of investors towards Petros Pharmaceuticals.
  

Petros Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Petros Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Rece...
Yahoo News
over six months ago at seekingalpha.com         
Petros Pharmaceuticals files 100M mixed securities shelf
seekingalpha News
over six months ago at news.google.com         
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health - Mark...
Google News at Macroaxis
over six months ago at accesswire.com         
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement wi...
news
over six months ago at finance.yahoo.com         
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement wi...
Yahoo News
over six months ago at investing.com         
Petros Pharmaceuticals partners with Lemonaid Health for ED drug distribution
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technol...
Yahoo News
over six months ago at investing.com         
Petros Pharmaceuticals advances STENDRA OTC switch plans
Investing News at Macroaxis
over six months ago at accesswire.com         
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technol...
news
over six months ago at simplywall.st         
Petros Pharmaceuticals Full Year 2023 Earnings Misses Expectations
Simply Wall St News at Macroaxis
over six months ago at investing.com         
Petros study shows web app aids OTC drug selection
Investing News at Macroaxis
over six months ago at investorplace.com         
PTPI Stock Earnings Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
sbwire news
over six months ago at accesswire.com         
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection Study fo...
news
over six months ago at finance.yahoo.com         
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection Study fo...
Yahoo News
over six months ago at news.google.com         
Should You Accumulate Petros Pharmaceuticals Inc Stock Monday Morning - InvestorsObserver
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Petros Pharmaceuticals that are available to investors today. That information is available publicly through Petros media outlets and privately through word of mouth or via Petros internal channels. However, regardless of the origin, that massive amount of Petros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Petros Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Petros Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Petros Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Petros Pharmaceuticals alpha.

Petros Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA
09/11/2024
2
Insider Trading
09/20/2024
3
Acquisition by John Shulman of 3382416 shares of Petros Pharmaceuticals subject to Rule 16b-3
10/04/2024
4
Acquisition by John Shulman of 1661807 shares of Petros Pharmaceuticals at 1.715 subject to Rule 16b-3
11/08/2024
5
Its Probably Less Likely That Petros Pharmaceuticals, Inc.s CEO Will See A Huge Pay Rise This Year
11/13/2024
6
Acquisition by Gesek Andrew of tradable shares of Petros Pharmaceuticals at 3.99 subject to Rule 16b-3
11/20/2024

Complementary Tools for Petros Stock analysis

When running Petros Pharmaceuticals' price analysis, check to measure Petros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Petros Pharmaceuticals is operating at the current time. Most of Petros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Petros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Petros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Petros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like